Ardelyx hit with class action over payer disclosures
Alpha Vantage · The National Law Review · · AI-summarised by FinFlash
Bronstein, Gewirtz & Grossman filed a class action against Ardelyx and certain officers, alleging misleading statements about rising payer-related access and reimbursement barriers affecting patient access to XPHOZAH and IBSRELA, which hurt commercial performance. Investors who bought securities between January 13, 2025 and August 6, 2026 must contact the firm by November 16, 2026 to seek lead plaintiff status.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.